A B S T R A C T

Background
Abnormal biliary secretion leads to the thickening of bile and the formation of plugs within the bile ducts; the consequent obstruction and abnormal bile flow ultimately results in the development of cystic fibrosis-related liver disease. This condition peaks in adolescence with up to 20% of adolescents with cystic fibrosis developing chronic liver disease. Early changes in the liver may ultimately result in end-stage liver disease with people needing transplantation. One therapeutic option currently used is ursodeoxycholic acid. This is an update of a previous review.
Objectives
To analyse evidence that ursodeoxycholic acid improves indices of liver function, reduces the risk of developing chronic liver disease and improves outcomes in general in cystic fibrosis.
Search methods
We searched the Cochrane CF and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches, handsearches of relevant journals and abstract books of conference proceedings. We also contacted drug companies and searched online trial registries.
Date of the most recent search of the Group's trials register: 09 April 2017.
Selection criteria
Randomised controlled trials of the use of ursodeoxycholic acid for at least three months compared with placebo or no additional treatment in people with cystic fibrosis.
Data collection and analysis
Two authors independently assessed trial eligibility and quality. The authors used GRADE to assess the quality of the evidence.
Main results
Twelve trials have been identified, of which four trials involving 137 participants were included; data were only available from three of the trials (118 participants) since one cross-over trial did not report appropriate data. The dose of ursodeoxycholic acid ranged from 10 to 20 mg/kg/day for up to 12 months. The complex design used in two trials meant that data could only be analysed for subsets of participants. There was no significant difference in weight change, mean difference -0.90 kg (95% confidence interval -1.94 to 0.14) based on 30 participants from two trials. Improvement in biliary excretion was reported in only one trial and no significant change after treatment was shown. There were no data available for analysis for long-term outcomes such as death or need for liver transplantation.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Ursodeoxycholic acid compared with control for cystic fibrosis-related liver disease Patient or population: adults and children with cystic f ibrosis-related liver disease Settings: outpatients ⊕ very low 2, 3 The outcom e 'Need f or liver transplantation' was not specifically reported. Inf orm ation regarding how m any individuals in each trial received liver transplants was available Long-term data f rom one trial (Colom bo 1996) showed that six participants across the entire cohort received a liver transplant Long-term data f rom one trial (Colom bo 1996) showed that 13 participants across the entire cohort died. 
M ortality
Nutritional status: change in weight (kg)
Follow
Improved abnormal biliary excretion
Follow-up: 6 m onths
There was no signif icant change in biliary excretion af ter treatm ent with UDCA NA 12 (1 trial) ⊕⊕ low 4, 5 M easured in the included trial as the tim e (in m inutes) f rom injection of the isotope to m axim al hepatic activity and the percentage clearance of isotope f rom the liver and biliary tree, at 45 and 60 m inutes com pared with m axim al activity
B A C K G R O U N D Description of the condition
Cystic fibrosis (CF) is a common inherited disease which invariably leads to progressive lung damage. The medical management of associated chronic chest disease has improved greatly over the last 30 years leading to improvement in survival well into adult life. Clinicians are now examining ways of both treating and delaying the progression of the disease in other affected organs. Among these, CF-related liver disease is clinically the most significant hepatic complication with a large impact on morbidity and mortality (Leeuwen 2014). A recent review suggested that hepatobiliary disease is the most common non-pulmonary cause of mortality in CF (the third after pulmonary disease and transplant complications) (Parisi 2013). A recent epidemiological study reported that there was a significantly higher prevalence of CF-related hepatobiliary abnormalities in people with CF under 18 years of age and 25% of those with CF-related hepatobiliary abnormalities developed hepatobiliary disease (Bhardwaj 2009).
The mechanism of liver involvement in CF is thought to be due to a chloride channel defect causing abnormal biliary secretion which leads to the thickening of bile and the formation of plugs within the bile ducts. The resulting ductular obstruction and abnormal bile flow ultimately results in the development of bile duct irregularities inside and outside the liver and cirrhosis in one or several parts of the liver. Therefore, therapy has been directed towards attempting to improve biliary secretion and bile acid composition.
Description of the intervention
Ursodeoxycholic acid (UDCA) is a naturally occurring hydrophilic bile acid. It is usual to take UDCA by mouth twice or three times a day, initially for several months but possibly indefinitely. Side effects are rare but diarrhoea has been reported. In 2003, the cost of six months' (24 weeks) treatment with UDCA for a 10-year old child weighing 25 kg, at a dose of 20 mg/kg/day, was £131 (RLCH 2003) . Colombo demonstrated in a dose-response study that the biochemical response to UDCA was best with a dose of 20 mg/ kg/day (Colombo 1992).
How the intervention might work
In 1990, Erlinger showed that UDCA improves bile acid flow by inducing a bicarbonate-rich bile flow (Erlinger 1990 ). This mechanism has potential use for people with CF-related liver disease in whom the bile ducts are blocked by thick and sticky secretions. Also, UDCA is not as toxic to the liver as other primary bile acids. Initially, UDCA was used in the treatment of gallstones (Roda 1982) and more recently as a possible treatment for other chronic liver diseases such as primary biliary cirrhosis (Poupon 1991) and primary sclerosing cholangitis (Beuers 1992). Over the last few years it has been used in the treatment and prevention of progression of CF-related liver disease following the observation of its therapeutic effectiveness in these other cholestatic conditions.
Why it is important to do this review
There are a number of debates surrounding the treatment of people with CF who have liver involvement. Both early detection and assessment of progression of liver disease in CF are relatively difficult. This is because by the time liver disease is evident in a person with an enlarged liver or spleen, there is often already raised pressure in the large vein running through the liver (portal hypertension, usually an irreversible event) and end-stage liver damage (cirrhosis). At this stage the only helpful treatment may be a liver transplant. These problems mean that clinicians are faced with the dilemma of when UDCA should be commenced: early to prevent liver involvement; or later as a therapeutic option. Another debate is how liver involvement can be evaluated. The important outcomes are death and preventing liver transplantation; other surrogate markers are often used but there are problems associated with these. Biochemical measures of liver function may not be useful because the level of abnormality does not always correlate with the extent of liver involvement (Tanner 1992).
Abnormalities of these test results may also be due to an effect other than CF liver disease, such as an effect of a drug treatment (Tanner 1992). Ultrasound can be used to assess the presence and progression of liver disease (Carty 1995). It can show alterations in liver size and texture and can also be used to assess the extent and direction of blood flow in the portal vein. However, results may vary with different operators. Another technique for identifying liver disease is radioisotope scanning (hepatobiliary scintigraphy) (O'Connor 1996) . Measuring the hepatic excretion of the compound 99mTc-HIDA allows an objective measurement of liver function and bile acid secretion. However, these are all intermediate outcomes and their correlations with the outcomes of death and liver transplantation are unknown. Although UDCA is relatively inexpensive compared to other treatments taken by people with CF (see above), it is yet another treatment of many and it is important that it has been shown to be effective. Therefore, we have undertaken a systematic review assessing its effectiveness in people with CF with liver involvement. This is an updated version of earlier versions of the review (Cheng 1997; Cheng 1999; Cheng 2012; Cheng 2014).
O B J E C T I V E S
To analyse evidence from randomised controlled trials (RCTs) in CF that UDCA improves indices of liver function, reduces the risk of developing chronic liver disease and improves outcomes in general in CF.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs (published or unpublished). Trials where pseudo-randomisation methods are used, such as alternation, will be included.
Types of participants
Children and adults with defined CF, diagnosed clinically and by sweat test or genetic testing, including all ages, all degrees of severity of disease and any degree of liver involvement.
Types of interventions
UDCA administered orally, at any dose, given for a period of at least three months compared to a control group receiving either placebo or no additional therapy (i.e. both groups receiving usual CF therapy). 
Types of outcome measures
Search methods for identification of studies
We searched for all relevant published and unpublished trials without restrictions on language, year or publication status. 
Electronic searches
Searching other resources
Reference sections of any trials identified were checked for any further RCTs. In addition we undertook full text searching of theJournal of Pediatrics from 1988 to 1995. We also contacted the pharmaceutical companies that market UDCA: Hoechst Marion Roussel (Destolit ® ) and Consolidated Chemicals Ltd (Ursofalk ® ).
Data collection and analysis
Selection of studies
The two authors (KC and RS) independently applied the inclusion criteria to all potential reports.
Data extraction and management
We attempted to extract data from each RCT from the text, tables and figures. We recorded data on the number of participants with each outcome event, by allocated group, irrespective of compliance and whether or not the participant was later thought to be eligible or otherwise excluded from treatment or follow up. For continuous outcomes we recorded the mean change from baseline for each group and standard error or standard deviation.
Assessment of risk of bias in included studies
In order to assess the risk of bias in the included trials, we considered such aspects as generation of randomisation sequence and allocation concealment. If we regarded these as adequate then there was a low risk of bias to the trial; if we regarded these as inadequate, then there was a high risk of bias to the trial; and if they were considered unclear then the risk of bias was unclear too. We also considered the degree of blinding and the risk of bias increased as the number of people blinded to the intervention decreased. We also considered other risks of bias, e.g. from selective reporting.
Measures of treatment effect
We calculated a pooled estimate of the treatment effect for each outcome across trials. For binary outcomes we calculated, where possible, the odds of an outcome among treatment-allocated participants to the corresponding odds among controls. For continuous outcomes, where data were available, we calculated a pooled estimate of treatment effect by calculating the mean difference (MD) and 95% confidence intervals (CIs).
Unit of analysis issues
Although we did not specifically excluded cross-over trials, we were concerned about the use of a cross-over design. This was because there may be a carry-over effect of UDCA in the control arm. We did include one cross-over trial in this review (Merli 1994) . The data presented in the published report appeared to be combined from both treatment periods, but the authors attempted to overcome a possible carry-over effect of UDCA by using a onemonth washout period. However, we considered it appropriate to compare only the first six months of the trial, i.e. UDCA versus placebo. Data from the first period were not available in the published report but the authors kindly provided the raw data. Including data from the first period in cross-over trials in meta-analyses is not without problems. Excluding later periods loses some of the information collected. Furthermore, if data from the first period are available in published reports they are likely to represent a biased subset of trials, usually because the authors have found evidence of carry-over (Elbourne 2002).
Dealing with missing data
Where sufficient data were not available in the published reports or the abstract of the conference proceedings, the review authors attempted to contact the first and last authors of the paper. We recorded data on the number of participants with each outcome event, by allocated group, irrespective of compliance and whether or not the participant was later thought to be eligible or otherwise excluded from treatment or follow up. This approach permits an intention-to-treat analysis.
Assessment of heterogeneity
We tested for heterogeneity between trial results using a standard Chi² test.
Data synthesis
We analysed the data using a fixed-effect model. If, in future updates of this review, we identify a moderate to large degree of heterogeneity, we will analyse the data using a random-effects model.
Subgroup analysis and investigation of heterogeneity
For future updates, if heterogeneity is identified and there are sufficient trials included in the review, we plan to investigate heterogeneity by means of examining individuals with evidence of liver disease at randomisation separately from those without liver disease.
Sensitivity analysis
We will also examine the robustness of our results using a sensitivity analysis including and excluding trials with a high risk of bias.
Summary of findings and quality of the evidence (GRADE)
In a post hoc change in line with current Cochrane guidance, at the 2017 update we added a summary of findings table (Summary of findings for the main comparison). We selected the following seven outcomes to report (chosen based on relevance to clinicians and consumers).
1. Change of hepatocellular enzymes from outside the normal range on at least one occasion to within the normal range of the method stated 2. Abnormally large livers reduced to within normal limits, as measured by ultrasound 3. Need for liver transplantation 4. Mortality 5. Nutritional status 6. Development of portal hypertension 7. Improved abnormal biliary excretion We determined the quality of the evidence using the GRADE approach; and downgraded evidence in the presence of a high risk of bias in at least one trial, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results, high probability of publication bias. We downgraded evidence by one level if they considered the limitation to be serious and by two levels if very serious. 
R E S U L T S Description of studies
Included studies
Four trials meet the inclusion criteria (Colombo 1996; Lepage 1997; Merli 1994; O'Brien 1992). One included trial is of crossover design but from the full published paper it is unclear whether there was any washout period employed and furthermore, data are not published for the first six-month period of the trial; thus we are unable to extract appropriate data for analysis (Lepage 1997). As such, we are only able to present results from three trials (Colombo 1996; Merli 1994; O'Brien 1992). Four trials with a total of 137 participants are included in the review, but results are only available from three trials involving a total of 118 participants (Colombo 1996; Merli 1994; O'Brien 1992). The ages of the participants ranged from 4 years to 32 years. The dose of UDCA given ranged from 10 to 20 mg/kg/day. In three trials the comparison was with placebo (Colombo 1996; Lepage 1997; Merli 1994). In the fourth trial the comparison was with existing conventional therapy (O'Brien 1992). In three of the trials all of the participants had liver disease (Colombo 1996; Lepage 1997; O'Brien 1992), whereas in the third trial only 10 out of 51 participants had liver disease (Merli 1994). The length of follow-up was generally short and ranged from six months (Merli 1994; O'Brien 1992) to 12 months (Colombo 1996; Lepage 1997). Important long-term outcomes such as death or the need for liver transplant were not reported. Only two of our protocol-defined outcomes were assessed: the nutritional indices (weight gain and skinfold thickness (Merli 1994; O'Brien 1992)); and biliary excretion (O'Brien 1992). Trial design was complicated in three trials (Colombo 1996; Lepage 1997; Merli 1994).
In the Merli cross-over trial, 51 participants were randomised to receive UDCA alone or with taurine for six months and then each treatment group was compared with a six-month placebo period (Merli 1994). The sequence of treatment and placebo was then randomised in a cross-over design. The data presented in the published report of the cross-over RCT appeared to be combined from both treatment periods. Although we had not specifically excluded cross-over trials, we were concerned about the use of a cross-over design. This was because there may be a carry-over effect of UDCA in the control arm, although the authors attempted to overcome this by using a one-month washout period. However, we considered it appropriate to compare only the first six months of the trial, i.e. UDCA versus placebo. Data from the first period were not available in the published report but the authors have kindly provided the raw data. Including data from the first period in crossover trials in meta-analyses is not without problems. Excluding later periods loses some of the information collected. Furthermore, if data from the first period are available in published reports they are likely to represent a biased subset of trials, usually because the authors have found evidence of carry-over (Elbourne 2002). In a further cross-over trial we were unable to ascertain whether a washout period was employed and data were not presented for the first treatment period; we have not been able to clarify this information and have therefore decided not to present any results from this trial (Lepage 1997). A factorial parallel design was employed in the Colombo trial (Colombo 1996) . In this multicentre trial, 55 participants were randomised to receive UDCA or placebo and then each group was further randomised to receive either taurine or a second placebo. In effect, four parallel groups were studied. In the O'Brien trial, 12 participants were randomised to UDCA or no additional therapy for six months (other than usual CF treatments, such as pancreatic enzymes and oral calorie supplements, which the UDCA group also received) (O'Brien 1992). Advanced liver disease, as documented by portal hypertension or histological features of fibrosis or cirrhosis or all three, was present in 11 out of 12 participants. The use of taurine in two trials also complicated their design and analysis since taurine may affect liver involvement in CF (Colombo 1996; Merli 1994). Although UDCA is known to cause taurine depletion, the combined effect of UDCA and taurine on liver function is unknown. These possible interactions and the complex trial designs caused difficulties when we considered combining the data. We have used subsets of the sample sizes given in the 'Characteristics of included studies' table so the participant numbers evaluated in the data tables and figures do not always tally with the sample sizes. In the Merli cross-over trial we decided only to use data from the first six months of the UDCA/placebo group and not use the UDCA plus taurine group (Merli 1994). This gave us data on an unbalanced number of participants in the two groups in the first six-month period: only six participants in the UDCA group and 12 partici-pants in the control group (51 were initially randomised). In the factorial, parallel trial we decided not to use data from participants who received taurine (hence the total number of participants used in the data tables was 28 not 55) (Colombo 1996) . However, only four of these 18 participants in this subset had abnormal liver enzymes at baseline. Another issue of the Merli cross-over RCT was that although weight, height and body mass percentile were measured, we had concerns about this type of trial design (Merli 1994). We would expect there to be a period effect on variables such as weight and height and this would require more subtle analysis. Again, we decided to use data only from participants in the UDCA-alone group and from the first six months of the trial before cross over. In 2005, Colombo presented follow-up survival data (obtained by a data collection form sent to each centre) from the RCT that had been conducted in 1990 (Colombo 1996) . Information was obtained from 53 of the original 55 participants (two were lost to follow-up) for a median total period of follow-up of 13.6 years; follow-up data for the whole cohort were presented, not by randomised group. The majority of the trial participants had continued open UDCA therapy after the end of the trial (median daily dose 666 mg).
Excluded studies
Eight trials were excluded in total. Three trials were excluded because they did not include a placebo arm or a 'no UDCA' arm (Colombo 1992; NCT00004441; Van de Meeberg 1997). One trial was not an RCT (Narckewicz 1994). Two trials were of insufficient duration; in one the duration of follow up was only six weeks (Bittner 1989) and in the final cross-over trial each treatment arm lasted four weeks (NCT00004315). Two trials were only published as abstracts (no full papers) with insufficient detail to confirm they meet the inclusion criteria; given the age of the abstracts, it is unlikely that any further publications relating to this trial will be forthcoming and therefore the trials have been excluded (Kapustina 2000; Spray 2000).
Risk of bias in included studies
Allocation All four trials were described as randomised, but only one trial stated the method used (Colombo 1996). We therefore judged the Colombo trial to have a low risk of bias (Colombo 1996) , and the remaining three trials to have an unclear risk of bias (Lepage 1997; Merli 1994; O'Brien 1992). Two trials described how allocation was concealed and these were judged to be adequate and hence have a low risk of bias (Colombo 1996; O'Brien 1992). The remaining two trials did not discuss allocation concealment and so were judged to have an unclear risk of bias (Lepage 1997; Merli 1994).
Blinding
One of the trials was described as double-blinded and we judged this to have a low risk of bias (Colombo 1996). In the Merli trial, glucose tablets were used as the placebo, so it is probable, although not explicitly stated, that the participants at least were blinded to whether they were in the treatment or control group, due to this uncertainty we judged this to have an unclear risk of bias (Merli 1994). The Lepage trial did not describe the placebo or any other aspect of blinding so it was not possible to ascertain whether the participants or the trial personnel were blinded to treatment groups and this trial was also judged to have an unclear risk of bias (Lepage 1997). It was not possible to blind the O'Brien trial to participants or clinicians since the participants either received UDCA or no additional treatment, it was not discussed whether outcome assessors were blinded; and we therefore judged this trial to have a unclear risk of bias (O'Brien 1992).
Incomplete outcome data
An intention-to-treat analysis was performed in two trials (low risk of bias) (Colombo 1996; O'Brien 1992). In one trial 51 participants were initially recruited, but nine subsequently withdrew (Merli 1994). These participants were not followed up and were not included in the analysis; data from a further two participants were identified as being lost when the raw data were provided (high risk of bias). In the fourth trial six out of 19 participants withdrew; reasons were given for all six (unclear risk of bias) (Lepage 1997).
Other potential sources of bias
In the Colombo trial the characteristics of the two groups were not equal at baseline; the paper states that all five participants with oesophageal varices and seven out of eight participants with abnormal serum bilirubin levels at entry were allocated to the UDCA group (high risk of bias) (Colombo 1996). One cross-over trial does not clearly report whether there was any washout period and data are not published for the first six-month period of the trial (unclear risk of bias) (Lepage 1997). For the remaining two trials no other potential sources of bias were identified (low risk) (Merli 1994; O'Brien 1992).
Effects of interventions
See: Summary of findings for the main comparison The authors of the two six-month trials have kindly provided us with raw data (personal communication) (Merli 1994; O'Brien 1992). Where possible we have entered quantitative data, but the use of complicated trial designs has meant that we have had to use subsets of small sample sizes. In one cross-over trial it is unclear whether there was any washout period employed and data are not published for the first six-month period of the trial; therefore while we have listed the trial as included, we are not able to present any results as we are unable to extract appropriate data (Lepage 1997).
Primary outcomes 1. Reduction of raised hepatocellular enzymes to within normal range of the method stated
We wished to examine the effect of UDCA on abnormal liver biochemistry by comparing the numbers of participants in both groups whose liver enzymes fell to within the normal range of the method stated at various time points. This was not reported as an outcome measure in any of the three RCTs but, serving as a proxy for this, the improvement in abnormalities of liver function was measured in all three RCTs. Raw data were available from two of the RCTs to enable us to examine this outcome (personal communication) (Merli 1994; O'Brien 1992). We assessed this outcome in three different ways (all with a very low quality of evidence): normalisation of any liver enzyme reported, odds ratio (OR) 0.09 (95% CI 0.01 to 1.24) (Analysis 1.1); normalisation of all liver enzymes reported (OR not estimable as there were no participants in either of the two trials with all enzymes normalised) (Analysis 1.2); and normalisation of individual liver enzymes (OR less than one for three out of four enzymes but the CIs were very wide) (Analysis 1.3; Analysis 1.4; Analysis 1.5; Analysis 1.6). For aspartate transaminase the OR was greater than one, again with a wide CI (Analysis 1.4).
Reduction of abnormally large livers as measured by ultrasound
The effect on liver size was not reported in any of the RCTs.
Liver transplantation
Need for liver transplantation was not specifically used as an outcome measure in any of the RCTs. However, one trial reported that one participant, who initially had multilobular cirrhosis and oesophageal varices (advanced liver involvement) and was allocated to treatment with UDCA, was subsequently withdrawn due to further deterioration of liver function (Colombo 1996) . This participant proceeded to liver transplantation. However, the CI of the OR generated was very wide and it was not possible to draw any conclusions about the effect of UDCA on the need for transplants (very low quality of evidence) (Analysis 1.7) Need for liver transplantation was reported as an outcome in the long-term follow-up data from the Colombo trial (Colombo 1996). Six participants underwent liver transplantation. However, these long-term data were reported as follow up for the whole cohort, not by randomised group. Therefore, it is not possible to draw any firm conclusions about the effect of UDCA therapy on the need for liver transplantation from these data. None of the participants in the two six-month trials required liver transplants (personal communication) (very low quality of evidence) (Merli 1994; O'Brien 1992) (Analysis 1.7).
Secondary outcomes 1. Mortality
Mortality was not reported in any of the RCTs (low quality of evidence), but there were no deaths in the two six-month trials (personal communication) (Merli 1994; O'Brien 1992) (Analysis 1.8; Analysis 1.9) Mortality was presented in the long-term follow-up data of the Colombo trial which reported 13 deaths; none of which were due to liver disease (Colombo 1996). However, these long-term data were reported for the whole cohort, not by randomised group. Therefore, it is not possible to draw any firm conclusions about the effect of UDCA therapy on mortality from these data.
Change in weight
Nutritional indices were one of only two pre-defined outcomes reported in the published reports. Weight gain was reported in only one of the RCTs (O'Brien 1992). However, measures of weight before and after six months' treatment were reported in another RCT (Merli 1994). Using the raw data of weight measurements before and after treatment or control in the two six-month trials (Merli 1994; O'Brien 1992), we calculated the weight change for each participant and then the mean and standard deviation for each trial (note: we again used only 18 out of 51 participants in the cross-over trial (Merli 1994)); MD -0.90 kg (95% CI -1.94 to 0.14) (low quality of evidence) (Analysis 1.10). Skinfold thickness was reported in two RCTs (Merli 1994; O'Brien 1992). Body mass percentile, which also takes into account the population mean weight and height rather than body mass index (weight in kilograms divided by height squared in metres), was reported in one trial (Merli 1994). The available post-treatment data (at six months) for the anthropometric outcomes reported in the Merli and O'Brien papers are presented in the table below.
Outcome measure
Trial
Result at 6 months (mean (SD))*
Ursodeoxycholic acid Control
Height ( 
Development of portal hypertension (raised pressure in the vein running through the liver) or its complications
These were not reported as outcome measures in any of the RCTs. However, it was confirmed (personal communication) that in the two six-month follow-up RCTs portal hypertension did not develop in any of the participants (low quality of evidence) (Merli 1994; O'Brien 1992) (Analysis 1.11; Analysis 1.12).
Improvement of biliary excretion
This outcome was reported in only one trial (O'Brien 1992). The original trial investigators measured the time (in minutes) from injection of the isotope to maximal hepatic activity and the percentage clearance of isotope from the liver and biliary tree, at 45
and 60 minutes compared with maximal activity. No significant changes in biliary excretion occurred after treatment with UDCA (low quality of evidence).
D I S C U S S I O N
This systematic review was first conducted in 1995 and over the intervening 22 years, no new meaningful clinical trial data have become available to change the original conclusions.
Summary of main results
This first systematic review on the effectiveness of ursodeoxycholic acid (UDCA) in cystic fibrosis (CF) highlights the paucity of randomised controlled trials (RCTs). There have been no RCTs investigating UDCA for preventing the development of liver disease in people with CF. Disappointingly, the few RCTs carried out have not adequately examined our pre-defined outcome measures, but they do provide important preliminary information which requires further evaluation. There was considerable variation in the outcome measures examined in the three RCTs and in the time points at which they were measured. This review has shown the absence of any significant effects of UDCA treatment on people with CF, apart from a slight effect on the surrogate endpoint of reduction of raised liver enzymes to normal. The information received from the authors of the six-month trials showed that no participants died, needed liver transplants or developed portal hypertension (Merli 1994; O'Brien 1992). However, these are short-term trials and there is insufficient evidence to show that UDCA improves survival or reduces the need for liver transplantation. We failed to show a significant effect of UDCA on weight change; but this is not the most appropriate way of assessing change in nutritional status (see below). The only trial that assessed the effect of UDCA on biliary excretion failed to demonstrate any significant change after treatment (O'Brien 1992). Although in our quantitative analysis we excluded data on participants who also received taurine, we will briefly mention individual trial results. The Merli trial showed that a six-month period of UDCA with or without taurine did not significantly affect the nutritional status (Merli 1994), whilst Colombo failed to show an effect of UDCA on liver enzymes (Colombo 1996).
Overall completeness and applicability of evidence
It is difficult to draw any meaningful conclusions from these results which are taken from small numbers of participants. Furthermore, several clinically meaningful outcomes, such as portal hypertension, liver transplantation and survival were not assessed. A number of surrogate endpoints have been reported; however, we cannot be sure that these actually correlate with important endpoints. For example, there is no evidence of a clear correlation between the serum level of hepatocellular enzymes and the degree of liver disease. Change in weight is not the most appropriate way of assessing any change in nutritional status. This is because we would expect children to gain weight over time, but expect the weight of adults to remain stable. It would be more appropriate to use indices such as body mass index or weight for height as a z score (where weight is expressed as a percentage of ideal for height and then compared with the standard deviation for the population). In this review we have included trials with a non-homogenous population (Merli 1994) and have, therefore, considered both possible preventative and therapeutic effects of UDCA in the same review. As we cannot be sure how raised levels of certain liver enzymes correlate with liver involvement (or whether absence of raised enzymes indicates a lack of liver involvement), we decided that we would lose important information if this trial were excluded.
Quality of the evidence
Although we had not specifically excluded cross-over trials, we were concerned about the use of a cross-over design. This was because there may be a carry-over effect of UDCA in the control arm, although the authors of the included cross-over trial attempted to overcome this problem by using a one-month washout period.
However, we considered it appropriate to compare only the first six months of the trial, i.e. UDCA versus placebo. We were only able to perform a limited quantitative meta-analysis due to the lack of data on clinically relevant endpoints and the different time points at which outcomes were measured. However, this systematic review provides an important summary of the information currently available from RCTs on the use of UDCA. This information may be used to inform the design of subsequent RCTs.
Overall, the quality of the evidence identified ranged from low to very low (Summary of findings for the main comparison).
Potential biases in the review process
We have undertaken comprehensive searches, including attempts to source unpublished data, to ensure that we have not failed to identify any potentially eligible RCTs. The authors have independently assessed the search results and extracted data in order to minimise any possible errors.
Agreements and disagreements with other studies or reviews
We have been unable to find any other similar reviews of UDCA in CF or any further studies other than the ones we have already included or excluded. Although UCDA is often used for the prevention or treatment of CF-related liver disease, recommendations from guidelines are inconsistent and not based on robust evidence (CF Trust 2011; CF Trust 2016; Debray 2011; Sokol 1999).
A U T H O R S ' C O N C L U S I O N S Implications for practice
Although UDCA is relatively inexpensive compared to other CF treatments, it would need to be taken on a long-term basis if it is effective. If it is ineffective then the resources saved by not using it could be used for other aspects of CF care.
Evidence of the effectiveness of UDCA is inconclusive. Routine use of UDCA in people with CF cannot, therefore, be justified. However, in view of these important preliminary results and because of the lack of any other effective intervention to prevent or treat CF-related liver disease, it is essential that a large multicentre RCT of UDCA in people with CF is undertaken.
Implications for research
The results of this systematic review indicate that there is an urgent need for a well-designed, adequately powered, multicentre RCT assessing the effectiveness of UDCA by measuring clinically relevant end points over years rather than months. Ideally a parallel trial, not a cross-over trial, should be undertaken. However, as there is insufficient evidence to indicate that UDCA is effective in CF, it is not possible to suggest how long it should be given, but long-term end points need to be assessed. Future trials should define the target population clearly, with separate trials for those without clinically detectable liver disease (the preventative effect) and those with liver disease (the therapeutic effect). In view of the problems of defining and assessing progression of liver involvement as well as the problem that by the time liver involvement is detected, it is too advanced for treatment, we suggest that the former is carried out first.
Although we have not been able to perform a formal meta-analysis, the RCTs we have identified show important preliminary results. 
A C K N O W L E D G E M E N T S
R E F E R E N C E S
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Colombo 1996
Methods Multi-factorial (4 parallel groups: initial randomisation to UDCA or placebo, then taurine or second placebo randomly added to participants), centrally computer-generated list, double-blind. Multicentre, 12 centres in Italy. 
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